Overexpression of lncRNA GATA6‑AS inhibits cancer cell proliferation in mantle cell lymphoma by downregulating GLUT1

Fan,Zhenwei; Wang,Xuan; Li,Peng; Mei,Chunli; Zhang,Min; Zhao,Chunshan

doi:10.3892/ol.2019.10540

Overexpression of lncRNA GATA6‑AS inhibits cancer cell proliferation in mantle cell lymphoma by downregulating GLUT1

Authors:
- Zhenwei Fan
- Xuan Wang
- Peng Li
- Chunli Mei
- Min Zhang
- Chunshan Zhao
View Affiliations

Affiliations: Nursing College of Beihua University, Jilin City, Jilin 132013, P.R. China, Department of Hematology, Affiliated Hospital of Beihua University, Jilin City, Jilin 132013, P.R. China, Department of Oncology, Jilin Central Hospital, Jilin City, Jilin 132000, P.R. China
Published online on: June 28, 2019 https://doi.org/10.3892/ol.2019.10540
Pages: 2443-2447
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA GATA6 antisense RNA 1 (lncRNA GATA6‑AS) is a recently identified lncRNA that is involved in endothelial‑mesenchymal transition. The present study aimed to investigate the involvement of GATA6‑AS in the progression of mantle cell lymphoma (MCL). It was found that plasma lncRNA GATA6‑AS expression level was downregulated in patients with MCL, compared with that in healthy controls. Downregulation of lncRNA GATA6‑AS has potential diagnostic value in early stage MCL. Overexpression of lncRNA GATA6‑AS resulted in inhibited glucose uptake in the human cell lines JVM‑2 and Z‑138 MCL. Inhibited expression of glucose transporter 1 (GLUT1) was observed in MCL cells following lncRNA GATA6‑AS overexpression, whilst GLUT1 overexpression did not alter the expression of lncRNA GATA6‑AS. Additionally, lncRNA GATA6‑AS overexpression inhibited, whilst GLUT1 overexpression promoted the proliferation of JVM‑2 and Z‑138 MCL cells; GLUT1 overexpression partially reversed the inhibitory effects of lncRNA GATA6‑AS overexpression. It was therefore concluded that lncRNA GATA6‑AS may inhibit cancer cell proliferation in MCL by downregulating GLUT1.

View Figures

View References

1	Chang DW, Satterfield WC, Son D, Neto N, Madewell JE, Raymond AK, Patrick CW Jr, Miller MJ, Costelloe CM and Weber KL: Use of vascularized periosteum or bone to improve healing of segmental allografts after tumor resection: An ovine rib model. Plast Reconstr Surg. 123:71–78. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, et al: Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med. 215:115–140. 2018. View Article : Google Scholar : PubMed/NCBI
3	Cheah CY, Seymour JF and Wang ML: Mantle cell lymphoma. J Clin Oncol. 34:1256–1269. 2016. View Article : Google Scholar : PubMed/NCBI
4	Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, et al: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 372:944–953. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, et al: Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 373:1835–1844. 2015. View Article : Google Scholar : PubMed/NCBI
6	Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, et al: 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): Prolonged remissions without survival plateau. Br J Haematol. 175:410–418. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hay N: Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy? Nat Rev Cancer. 16:635–649. 2016. View Article : Google Scholar : PubMed/NCBI
8	Liberti MV and Locasale JW: The warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
9	Olson AL and Pessin JE: Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 16:235–256. 1996. View Article : Google Scholar : PubMed/NCBI
10	Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X and Chen J: GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 78:86–94. 2018. View Article : Google Scholar : PubMed/NCBI
11	Oh S, Kim H, Nam K and Shin I: Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. BMB Rep. 50:132–137. 2017. View Article : Google Scholar : PubMed/NCBI
12	Neumann P, Jaé N, Knau A, Glaser SF, Fouani Y, Rossbach O, Krüger M, John D, Bindereif A, Grote P, et al: The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2. Nat Commun. 9:2372018. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Hu G, Gupta SK, Troska TP, Nair A and Gupta M: Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget. 8:80223–80234. 2017.PubMed/NCBI
15	Wang X, Sehgal L, Jain N, Khashab T, Mathur R and Samaniego F: LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 14:3462016. View Article : Google Scholar : PubMed/NCBI
16	Vose JM: Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 90:739–745. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zou ZW, Ma C, Medoro L, Chen L, Wang B, Gupta R, Liu T, Yang XZ, Chen TT, Wang RZ, et al: LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget. 7:61741–61754. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liu X and Gan B: lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1. Cell Cycle. 15:3471–3481. 2016. View Article : Google Scholar : PubMed/NCBI